EN

News

  • Personalized Medicine at the FDA – 2017 progress report

    31 May 2018

  • Pharmaceutical Industry representatives speak out on personalised medicine

    11 January 2018

  • (bio-)Pharmaceutical industry emphasizes the importance of Personalised Medicine

    27 November 2017

  • About the illusion of evidence-based practice in healthcare

    25 July 2017

  • RIVM analysis: Personalised medicine in medical practice

    26 June 2017

  • Focus on Personalised Medicine on the Pivot Park

    29 May 2017

Pharmaceutical Industry representatives speak out on personalised medicine

Thursday 11 January 2018

EUreporter interviewed senior managers from AstraZeneca and Merck on the effects Personalised Medicine has on their companies.

Video and summary statement:

David Boyd, Director European Government Affairs at AstraZeneca, accepted the award for ‘Patient-centric Innovator’ at the first annual congress of the European Association of Personalised Medicine (EAPM). Boyd said that it was great for AstraZeneca to be recognised for its patient focus. He said the day of the block-buster drug is gone, and that 80% of the medicines in their pipeline were now personalised. Boyd said that the new approach will require a shake-up in the healthcare system in order to get the right medicine, to the right people at the right time.

Video and summary statement:

Chris Round, Head of EMEA Region for Merck, says that there are better ways to work with patients to make sure that patient input is optimised in research and development. The use of bio-markers is one way that the right person gets the right drug. There is potential for individual drugs to raise costs, but there is also the potential that it could reduce costs by ruling out people who don’t respond to a medication. Round would like to see a really strong policy framework that supports the development of personalised medicine, he would also like to see the investment ‘infrastructure’ in diagnostic testing and roll-out bio-markers. In identifying those who will benefit, patients will benefit, payers will benefit and the whole system will become more efficient.